CD56 and CD11b Positivity with Low Smac/DIABLO Expression as Predictors of Chemoresistance in Acute Myeloid Leukaemia: Flow Cytometric Analysis |
| |
| Authors: | Abeer Ibrahim1Asmaa M Zahran2Sanaa Shaker Aly3Ahmed Refaat1Mohammed H Hassan4 |
| |
| Affiliation: | 1Department of Medical Oncology and Haematological Malignancies, South Egypt Cancer Institute, Assiut University, Egypt.2Department of Clinical Pathology, South Egypt Cancer Institute, Assiut University, Egypt.3Department of Clinical Pathology, Faculty of Medicine, South Valley University, Qena, Egypt.4Department of Medical Biochemistry-Faculty of Medicine- South Valley University, Qena, Egypt. |
| |
| Abstract: | Background: Resistance to chemotherapy is a major obstacle to curing acute myeloid leukaemia (AML), andseveral antigens are claimed to play primary roles in this resistance. Purpose: The aim of this study was to evaluatethe roles of CD56, CD11b and Smac/DIABLO gene expression levels as prognostic markers of the clinical outcome,response to chemotherapy and survival of AML patients. Materials and Methods: A cross-sectional observationalstudy was conducted on 60 naïve-AML patients who received induction therapy with mitoxantrone and cytarabinecombined with a high dose of cytarabine. The CD56,CD11b and Smac/DIABLO expression levels were assessed usingflow cytometry at diagnosis and were analysed for correlation with the possible associated risk factors, response tochemotherapy, and median duration of disease-free survival (DFS) and overall survival (OS). Results: The overall resultsrevealed that AML patients who exhibited positive expression for CD56 and CD11b had short median durations of DFSand OS.(P = 0.019, 0.006, 0.029 and 0.024, respectively). Additionally, low Smac/DIABLO expression had a negativeimpact on treatment outcome in terms of CR rate (p=0.012) and reduced DFS (p=0.000) and OS(p=0.000) values.Conclusions: CD56 and CD11b positivity and low Smac/DIABLO expression are important predictive factors forthe occurrence of chemoresistance, in addition to other risk factors, among AML patients. |
| |
| Keywords: | Chemoresistance CD56 CD11b Smac/DIABLO AML |
|
| 点击此处可从《Asian Pacific journal of cancer prevention》浏览原始摘要信息 |
|
点击此处可从《Asian Pacific journal of cancer prevention》下载免费的PDF全文 |
|
